Physician profile
Jennifer A Domm
NPI 1558395665
$359,445.29
in general payments reported to CMS, 2019-2025
63 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,507 · 2020: $19K · 2021: $13K · 2022: $99K · 2023: $52K · 2024: $66K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Travel and Lodging: $43K · Consulting Fee: $29K · Food and Beverage: $6,617 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,839.24 |
| Travel and Lodging | $42,705.04 |
| Consulting Fee | $28,943.00 |
| Food and Beverage | $6,617.42 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320,755.54 | 2019-2025 | Novoseven, Alhemo, Rebinyn |
| Pfizer INC. | $16,713.48 | 2021-2025 | |
| Csl Behring | $8,399.94 | 2019-2025 | Hemgenix, Idelvion |
| Takeda Pharmaceuticals U.S.A., INC. | $2,772.76 | 2019-2025 | Livtencity, Eohilia |
| Adaptive Biotechnologies Corporation | $2,510.58 | 2022 | |
| Biomarin Pharmaceutical INC. | $1,900.00 | 2025 | Roctavian |
| Pharmacosmos Therapeutics INC. | $1,638.43 | 2023 | Monoferric |
| Becton, Dickinson and Company | $400.00 | 2022 | |
| Recordati_rare_diseases_inc. | $353.00 | 2024 | |
| Tersera Therapeutics LLC | $313.00 | 2024 | |
| Dr.Reddy'S Laboratories,INC. | $245.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $229.06 | 2021-2024 | |
| Sobi, INC | $215.61 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $209.37 | 2022-2025 | Ultomiris, Koselugo |
| Pharming Healthcare, INC. | $163.59 | 2023-2025 | Ruconest |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.13 | 2021-2023 | Blincyto, Nplate |
| Biogen, INC. | $134.43 | 2023-2025 | Spinraza, Skyclarys, Spinraza |
| Vertex Pharmaceuticals Incorporated | $124.10 | 2024 | |
| Jazz Pharmaceuticals INC. | $123.57 | 2021-2025 | |
| Springworks Therapeutics, INC. | $122.57 | 2025 | Gomekli |
| Octapharma USA, INC. | $114.18 | 2020-2021 | |
| Genzyme Corporation | $110.33 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $107.65 | 2022-2025 | Pyrukynd |
| Ucb, INC. | $101.28 | 2023-2025 | Fintepla, Nayzilam |
| Azurity Pharmaceuticals, INC. | $97.40 | 2022-2025 | Eprontia, Zonisade, Xatmep |
| Uswm, LLC | $96.70 | 2024-2025 | Iwilfin |
| Insulet Corporation | $94.14 | 2019 | |
| Syndax Pharmaceuticals, INC. | $74.86 | 2025 | |
| Hema Biologics, LLC | $72.66 | 2023 | Sevenfact |
| Endo Pharmaceuticals INC. | $70.67 | 2019 | |
| Krystal Biotech INC | $67.94 | 2023-2024 | Vyjuvek |
| Y-Mabs Therapeutics, INC. | $65.51 | 2021-2022 | |
| Mesoblast, INC. | $62.03 | 2025 | Ryoncil |
| Arbor Pharmaceuticals, INC. | $53.22 | 2019 | |
| Genentech USA, INC. | $50.41 | 2023-2024 | Hemlibra |
| Aptevo Therapeutics INC | $50.21 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $49.28 | 2023-2024 | Fycompa |
| Day One Biopharmaceuticals | $47.57 | 2025 | Ojemda |
| Sanofi-Aventis U.S. LLC | $42.82 | 2023-2024 | |
| Kerecis Limited | $40.48 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medexus Pharma, INC. | $39.88 | 2023 | Ixinity |
| Grifols USA, LLC | $35.14 | 2019-2023 | Thrombate III |
| Corium, LLC | $34.71 | 2024 | Azstarys |
| Ultragenyx Pharmaceutical INC. | $32.23 | 2025 | |
| Seagen INC. | $31.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.94 | 2022 | |
| Companion Medical, INC. | $29.13 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $27.92 | 2025 | Bylvay |
| Aquestive Therapeutics, INC. | $26.28 | 2025 | |
| Immedica Pharma US, INC. | $21.64 | 2025 | Ztalmy |
| Sk Life Science, INC. | $21.60 | 2023 | |
| Amneal Pharmaceuticals LLC | $20.28 | 2023 | Lyvispah |
| Livanova USA, INC. | $19.26 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Mirum Pharmaceuticals, INC. | $17.99 | 2025 | Cholbam |
| Ferring Pharmaceuticals INC. | $16.54 | 2019 | |
| Janssen Biotech, INC. | $16.38 | 2022 | |
| Aucta Pharmaceuticals, INC. | $16.28 | 2024 | Motpoly Xr |
| Abbvie INC. | $15.59 | 2021 | |
| Phadia US INC. | $15.57 | 2021 | |
| Albireo Pharma, INC. | $15.39 | 2022 | |
| Tandem Diabetes Care, INC. | $13.92 | 2020 | |
| Global Blood Therapeutics, INC. | $13.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Domm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.